Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3386
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines.

    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
AC Immune
Active Biotech
Adaptimmune
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Amgen
Anavex Life Sciences
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
ApopLogic Pharmaceuticals
Apotex
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
BioAlliance Pharma
Biocompatibles
Biogen Idec
Biokine Therapeutics
BioLineRx
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chong Kun Dang
Choongwae
Circadian Technologies
Clavis Pharma
CLL Pharma
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
CuraGen
Curaxis
CureTech
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dong-A
Dynavax Technologies
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Etubics
Exelixis
FasTrack Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Hanmi
Heat Biologics
Heidelberg Pharma
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IkerChem
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kiadis
Kyowa Hakko Kirin
Labopharm
Leo
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
NovaRx
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Pfizer
Pharmaclon
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen Pharmaceuticals
Progenics Pharmaceuticals
Protherics
Radient Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
Scancell
Seattle Genetics
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Spirogen
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Viralytics
Virionics
ViroMed
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
ADXS11-001
AE-37
afatinib
aflibercept
AGS-003
amrubicin hydrochloride
Angiozyme
ANZ-207
ARQ-197
astuprotimut-r
Auto TAG vaccine
AVX-701
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
BP-GMAX-CD1
brivanib alaninate
BV-NSCLC-001
canfosfamide hydrochloride
capecitabine
catumaxomab
CB-10-01
CDX-1307
cediranib
celecoxib
cetuximab
CG-201
CreaVax-PC
crizotinib
CV-9103
CV-9201
CVac
dacomitinib
DCVax-prostate
docetaxel
doxifluridine
E-75
emepepimut-S
endostatin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
gefitinib
GI-4000
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
HS-110
icotinib hydrochloride
ICT-107
imMucin
IMO-2055
iniparib
interferon (gamma1b)
interferon gamma
interleukin-12
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
JX-594
lapatinib ditosylate
MDX-1379
MGN-1601
MGN-1703
motesanib diphosphate
MVA-BN Her-2 vaccine
nadroparin
necitumumab
nimotuzumab
oblimersen sodium
OncoVAX
Onyvax-105
OTS-102
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
paclitaxel polyglumex
panitumumab
pazopanib hydrochloride
pemetrexed disodium
perifosine
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
raltitrexed
ramucirumab
regorafenib
Reximmune-C
rindopepimut
rintatolimod
S-488410
SCIB-1
sipuleucel-T
sorafenib tosylate
Survivac
talactoferrin alfa
tegafur + uracil
tegafur + uracil + leucovorin
TG-4010
thymalfasin
tipapkinogene sovacivec
topotecan
TroVax
TS-1
velimogene aliplasmid
verpasep caltespen
vitespen
VX-001

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines.
    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lymphoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Breast Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Hedgehog Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More